CLAIMS:

1. An antibody or an antigen binding fragment thereof, that specifically binds to hOX40L , and inhibits binding of hOX40L to hOX40, and comprises a heavy chain and a light chain and wherein:

    the antibody or antigen binding fragment comprises a V_H domain which comprises:

        the HCDR1 sequence of SEQ ID NO:36 or 42;

        the HCDR2 sequence of SEQ ID NO:38 or 44; and

        the HCDR3 sequence of SEQ ID NO:40 or 46;

    and wherein the antibody or antigen binding fragment comprises a V_L domain which comprises:

        the LCDR1 sequence of SEQ ID No:50 or 56;

        the LCDR2 sequence of SEQ ID NO:52 or 58; and

        the LCDR3 sequence of SEQ ID NO:54 or 60.

2. An antibody or antigen binding antigen binding fragment according to claim 1, wherein:

    the heavy chain comprises a V_H region having at least 85% identity to the amino acid sequence of SEQ ID No:34; and

    the light chain comprises a V_L region having at least 85% identity to the amino acid sequence of SEQ ID No:48.

3. An antibody or antigen binding fragment according to any preceding claim, wherein the antibody or antigen binding fragment comprises a V_H domain comprising an amino acid sequence of SEQ ID NO: 34 and comprises a V_L domain comprising an amino acid sequence of SEQ ID NO:48.

4. An antibody or an antigen binding fragment thereof, that specifically binds to hOX40L, and inhibits binding of hOX40L to hOX40, and comprises a heavy chain and a light chain wherein:

    the antibody or antigen binding fragment comprises a V_H domain which comprises:

        the HCDR1 sequence of SEQ ID NO:4 or 10;

        the HCDR2 sequence of SEQ ID NO:6 or 12; and

        the HCDR3 sequence of SEQ ID NO:8 or 14;

    and wherein the antibody or antigen binding fragment comprises a V_L domain which comprises:

        the LCDR1 sequence of SEQ ID No:18 or 24;

        the LCDR2 sequence of SEQ ID NO:20 or 26; and

        the LCDR3 sequence of SEQ ID NO: 22 or 28.

5. An antibody or antigen binding antigen binding fragment according to claim 4, wherein:

the heavy chain comprises a V_H domain having at least 85% identity to the amino acid sequence of SEQ ID No:2 and

the light chain comprises a V_L domain having at least 85% identity to the amino acid sequence of SEQ ID No:16.

6. An antibody or antigen binding fragment according to claim 4 or 5, wherein the antibody or antigen binding fragment comprises a V_H domain comprising an amino acid sequence of SEQ ID NO: 2 and comprises a V_L domain comprising an amino acid sequence of SEQ ID NO:16.

7. An antibody or antigen binding fragment according to any preceding claim comprising first and second copies of said V_H domain.

8. An antibody or antigen binding fragment according to claim 7, comprising a human gamma 4 constant region.

9. An antibody or antigen binding fragment according to claim 8, comprising a heavy chain constant region which is IgG4 PE.

10. An antibody or antigen binding fragment according to claim 9, comprising a heavy chain constant region of Seq ID No:128.

11. An antibody or antigen binding fragment according to any preceding claim comprising first and second copies of said V_L domain.

12. An antibody or antigen binding fragment according to any preceding claim, wherein the antibody or antigen binding fragment comprises a kappa light chain.

13. An antibody or antigen binding fragment according to any preceding claim, wherein the antibody or antigen binding fragment comprises a kappa light chain comprising a constant region selected from the group consisting of the kappa light chain constant region amino acid sequences of Seq ID Nos: 136, 138, 140, 142 and 144.

14. An antibody or antigen binding fragment according to any preceding claim which is a fully human antibody.

15. An antibody according to any preceding claim, wherein the antibody comprises a heavy chain and a light chain, the heavy chain amino acid sequence consisting of the sequence of SEQ ID No:62 and the light chain amino acid sequence consisting of the sequence of SEQ ID No:64.

16. An antibody or antigen binding fragment according to any preceding claim wherein the antibody or antigen binding fragment competes for binding to said hOX40L epitope with the antibody 02D10, which antibody 02D10 comprises a V_H domain comprising the amino acid sequence consisting of the sequence of SEQ ID No:34 and a V_L domain comprising the amino acid sequence consisting of the sequence of SEQ ID No:48.

17. An antibody or antigen binding fragment according to any preceding claim which specifically binds to said hOX40L epitope with a Kd of from 1nM to 10pM as determined by SPR.

18. An antibody or antigen binding fragment according to any preceding claim which specifically binds to rhesus monkey OX40L epitope with a Kd of from 10nM to 100pM as determined by SPR.

19. A pharmaceutical composition comprising an antibody or antigen binding fragment as defined in any one of claims 1 to 18, and a pharmaceutically acceptable excipient, diluent or carrier.

20. A pharmaceutical composition according to claim 19, formulated for parenteral administration selected from intravenous or sub-cutaneous administration.

21. A pharmaceutical composition according to claim 19 or claim 20, further comprising a further therapeutic agent independently selected from the group consisting of rapamycin (sirolimus), tacrolimus, ciclosporin, corticosteroids (e.g. methylprednisolone), methotrexate, mycophenolate mofetil, anti-CD28 antibodies, anti-IL12/IL-23 antibodies (e.g. ustekinumab), anti-CD20 antibodies (e.g.rituximab), anti-CD30 antibodies (e.g. brentuximab), CTLA4-Fc molecules (e.g. abatacept), CCR5 receptor antagonists (e.g. maraviroc), anti-CD40L antibodies, anti-VLA4 antibodies (e.g. natalizumab), anti-LFA1 antibodies, fludarabine, anti-CD52 antibodies (e.g. alemtuzumab), anti-CD45 antibodies, cyclophosphamide, anti-thymocyte globulins, anti-complement C5 antibodies (e.g. eculizumab), anti-a4b7 integrin antibodies (e.g. vedolizumab), anti-IL6 antibodies (e.g. tocilizumab), anti-IL2R antibodies (e.g. basilixumab), anti-CD25 antibodies (e.g. daclizumab), anti-TNFa / TNFa-Fc molecules (e.g. etanercept, adalimumab, infliximab, golimumab or certolizumab pegol) and Vorinostat.

22. A pharmaceutical composition according to any one of claims 19 to 21, or a kit comprising a pharmaceutical composition as defined in any one of claims 19 to 21, wherein the composition is for treating and/or preventing a hOX40L-mediated disease or condition selected from an autoimmune disease or condition, a systemic inflammatory disease or condition, or transplant rejection; for example inflammatory bowel disease (IBD), Crohn's disease, rheumatoid arthritis, transplant rejection, allogenic transplant rejection, graft-versus-host disease (GvHD), ulcerative colitis, diabetes, uveitis, ankylosing spondylitis, contact hypersensitivity, and atherosclerosis, in particular GvHD.

23. An pharmaceutical composition according to any one of claims 19 to 21, or a kit comprising a pharmaceutical composition as defined in any one of claims 19 to 21, wherein the composition is for treating a hOX40L-mediated disease or condition selected from systemic lupus erythematosus (SLE) and multiple sclerosis.

24. A pharmaceutical composition according to any one of claims 19 to 23, or kit according to any one of claims 22 to 23, further comprising a label or instructions for use to treat and/or prevent said disease or condition in a human.

25. A pharmaceutical composition according to claim 24 or a kit according to claim 24, wherein the label or instructions comprise a marketing authorisation number (e.g., an FDA or EMA authorisation number).

26. A kit according to any one of claims 22 to 25, which comprises an IV or injection device that comprises the antibody or antigen binding fragment thereof.

27. An antibody or antigen binding fragment as defined in any one of claims 1 to 18 for use in therapy.

28. An antibody or antigen binding fragment according to claim 27, for use in treating or preventing a hOX40L-mediated disease or condition selected from an autoimmune disease or condition, a systemic inflammatory disease or condition, or transplant rejection.

29. An antibody or antigen binding fragment for the use according to claim 28, wherein the hOX40L-mediated disease or condition is selected from inflammatory bowel disease (IBD), Crohn's disease, rheumatoid arthritis, transplant rejection, allogenic transplant rejection, graft-versus-host disease (GvHD), ulcerative colitis, diabetes, uveitis, ankylosing spondylitis, contact hypersensitivity, and atherosclerosis.

30. An antibody or antigen binding fragment for the use according to claim 28, wherein the hOX40L-mediated disease or condition is dermatitis.

31. An antibody or antigen binding fragment according to claim 27, for use in treating a hOX40L-mediated disease or condition selected from systemic lupus erythematosus (SLE) and multiple sclerosis.

32. A nucleic acid that encodes a V_H domain and a V_L domain of an antibody or antigen binding fragment as defined in any one of claims 1 to 18.

33. A nucleic acid that encodes a nucleotide sequence that is at least 90% identical to the sequence of SEQ ID NO: 33 and SEQ ID NO: 47; or a nucleotide sequence that is at least 90% identical to the sequence of SEQ ID NO: 1 and SEQ ID NO: 15.

34. A nucleic acid that encodes a heavy chain and a light chain of an antibody or antigen binding fragment as defined in any one of claims 1 to 18.

35. A nucleic acid that encodes a V_H domain of an antibody as defined in any one of claims 1 to 15 or an antigen binding fragment as defined in any one of claims 1 to 13 and a nucleic acid that encodes a V_L domain of an antibody as defined in any of claims 1 to 15 or an antigen binding fragment as defined in any one of claims 1 to 13.

36. A vector comprising the nucleic acid as defined in any one of claims 32 to 35; optionally wherein the vector is a CHO or HEK293 vector.

37. A host cell comprising the nucleic acid as defined in any one of claims 32 to 35 or the vector as defined in claim 36.